Continuous Meropenem No Benefit in Critically Ill Patients With Sepsis
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, June 22, 2023 -- For critically ill patients with sepsis, continuous administration of meropenem does not improve a composite outcome of mortality and emergence of pandrug- or extensively drug-resistant bacteria compared with intermittent administration, according to a study published online June 16 in the Journal of the American Medical Association to coincide with the annual Critical Care Reviews Meeting, held from June 14 to 16 in Belfast, Northern Ireland.
Giacomo Monti, M.D., from the IRCCS San Raffaele Scientific Institute in Milan, and colleagues conducted a randomized trial involving critically ill patients with sepsis or septic shock who had been prescribed meropenem by their treating clinicians at 31 intensive care units of 26 hospitals. Patients were randomly assigned to receive an equal dose of meropenem by continuous or intermittent administration (303 and 304 patients, respectively).
Overall, 61 percent of the patients had septic shock. The researchers found that the primary outcome event (composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28) occurred in 47 and 49 percent of patients in the continuous and intermittent administration groups, respectively (relative risk, 0.96; 95 percent confidence interval, 0.81 to 1.13). None of the four secondary outcomes were statistically significant. There were no reports of adverse events of seizures or allergic reactions related to the study drug. In both groups, mortality was 42 percent at 90 days.
"The results of the current study suggest that continuous administration of meropenem does not improve clinically relevant outcomes in critically ill patients with sepsis, including long-term mortality," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Considerable Variation Seen in Mortality Rates for Suspected Sepsis
TUESDAY, May 28, 2024 -- There is considerable variation in mortality rates among patients with suspected sepsis, according to a research letter published online May 28 in the...
Acetaminophen Does Not Improve Survival in Adults With Sepsis
MONDAY, May 20, 2024 -- For adults with sepsis, intravenous acetaminophen is safe but does not significantly improve the number of days alive and free of organ support, according...
AI Model for Early Prediction of Sepsis Improves Outcomes
WEDNESDAY, Jan. 31, 2024 -- Deployment of COMPOSER for early prediction of sepsis is associated with significant improvements in outcomes, including mortality, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.